For those complaining about management, they have literally locked up all suppliers. Suppliers that have built factories to support the need and obtained patents. With an appeal and the EU up for grabs, what supplier is going to risk losing it all to support a generic? Amarin needs to sell as much as quickly as possible and keep contracts alive even if it risks throwing away inventory. <br> <br> <a href="https://www.outsourcing-pharma.com/Article/2013/08/27/Amarin-Asks-US-FDA-to-OK-Novasep-as-Vascepa-API-Supplier" rel="nofollow noopener noreferrer ugc" target="_blank">https://www.outsourcing-pharma.com/Article/2013/08/27/Amarin-Asks-US-FDA-to-OK-Novasep-as-Vascepa-API-Supplier</a> <br> <br> I think of it like non-fish oil. Russia and Saudi can reduce the price to increase their market share but they will end up screwing themselves in terms of profit.